arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Harrow, Inc.

HROW Health Care Biotechnology: Pharmaceutical Preparations
$38.54
Today
as of Sep 4, 16:50 ET
Last 30 days -1.98% Jul 28 → Sep 04
$36.50 $37.99 $39.49 $40.98 $42.47 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$37.96
High
$38.66
Low
$37.73
Volume
$229,010
Avg Vol
$704,053
Mkt Cap
$1.6B
P/E (TTM)
—
Beta
—
52w High
$54.85
52w Low
$28.54
Div Yield
—
Shares Out
$37M

Recent Press Releases & News last 60 days · 18 items

Sep 1 · 11:00 PR GlobeNewswire
Harrow to Participate in Three Investor Conferences in September
Aug 20 · 12:24 Insider Monkey
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target
Aug 20 · 11:46 MT Newswires
Harrow's IHEEZO Cuts Patient-Reported Discomfort 58% in Intravitreal-Injection Study
▸ Show all 18 press releases & news Free account →

Overview

52-week range
$29
$55
38% of range
Avg surprise (last 2)
-1,023%
Avg reaction (last 2)
-2.3%
0% positive
Latest IV / EM
68%
EM ±10.6% · $39 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.63$-0.41$-0.20$0.02$0.24 Actual $-0.22Actual $-0.14Actual $-0.13Actual $-0.38Actual $-0.18Actual $-0.12Actual $-0.38Est $0.02Actual $0.24Actual $0.03Actual $-0.63Est $-0.43Actual $-0.46 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-28M$-2M$24M$50M$75M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.46 — — — — financials
Mon May 11, 2026Mar/2026 $-0.63 $-0.43 -46.5% -65.8% -0.5% earnings
Tue Sep 30, 2025Sep 2025 $0.03 — — — — financials
Mon Aug 11, 2025Jun/2025 $0.24 — — — — earnings
Thu May 8, 2025Mar/2025 $-0.38 $0.02 -2,000% — -4.1% earnings
Mon Sep 30, 2024Sep 2024 $-0.12 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.18 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.38 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.13 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.14 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.22 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$71M$44M—$72M$64M$48M—$49M
Cost of revenue$20M$17M—$18M$16M$16M—$12M
Gross profit$50M$27M—$54M$48M$32M—$37M
Operating income$-11M$-22M—$15M$11M$-11M—$1M
Net income$-17M$-28M—$1M$5M$-18M—$-4M
EPS (diluted)$-0.46$-0.74—$0.03$0.13$-0.50—$-0.12

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$84M$95M$73M$74M$53M$67M$47M$73M
Inventory$17M$16M$14M$13M$12M$11M$11M$10M
Total current assets$229M$226M$212M$178M$155M$170M$190M$147M
Total assets$417M$420M$399M$363M$345M$364M$389M$352M
Long-term debt—$300M—$347M$251M$257M—$231M
Total liabilities$402M$391M$347M$316M$296M$308M$320M$294M
Total equity$15M$28M$52M$47M$49M$56M$70M$58M

Implied volatility — last 90 days

42%73%103%133%164% Jun 07 — IV 95% · EM ±13.1%Jun 08 — IV 65% · EM ±8.6%Jun 09 — IV 100% · EM ±12.6%Jun 10 — IV 70% · EM ±8.2%Jun 11 — IV 73% · EM ±8.1%Jun 12 — IV 92% · EM ±9.4%Jun 15 — IV 84% · EM ±6.1%Jun 16 — IV 130% · EM ±7.7%Jun 17 — IV 164% · EM ±6.9%Jun 19 — IV 54% · EM ±11.8%Jun 22 — IV 57% · EM ±11.9%Jun 23 — IV 60% · EM ±12.2%Jun 24 — IV 65% · EM ±13.1%Jun 25 — IV 62% · EM ±12.1%Jun 26 — IV 66% · EM ±12.6%Jun 29 — IV 68% · EM ±12.1%Jun 30 — IV 59% · EM ±10.2%Jul 01 — IV 46% · EM ±7.7%Jul 02 — IV 62% · EM ±10.0%Jul 03 — IV 64% · EM ±10.0%Jul 06 — IV 49% · EM ±6.8%Jul 07 — IV 63% · EM ±8.3%Jul 08 — IV 80% · EM ±10.0%Jul 09 — IV 72% · EM ±8.6%Jul 13 — IV 100% · EM ±8.4%Jul 15 — IV 116% · EM ±6.9%Jul 16 — IV 72% · EM ±3.0%Jul 20 — IV 81% · EM ±19.2%Jul 21 — IV 85% · EM ±19.7%Jul 22 — IV 85% · EM ±19.5%Jul 23 — IV 81% · EM ±18.2%Jul 24 — IV 82% · EM ±18.0%Jul 27 — IV 82% · EM ±17.2%Jul 28 — IV 85% · EM ±17.5%Jul 29 — IV 91% · EM ±18.2%Jul 30 — IV 98% · EM ±19.2%Jul 31 — IV 96% · EM ±18.3%Aug 03 — IV 108% · EM ±19.1%Aug 04 — IV 92% · EM ±15.8%Aug 05 — IV 110% · EM ±18.5%Aug 06 — IV 96% · EM ±15.5%Aug 07 — IV 89% · EM ±14.0%Aug 10 — IV 114% · EM ±15.8%Aug 11 — IV 79% · EM ±10.4%Aug 13 — IV 72% · EM ±8.5%Aug 14 — IV 86% · EM ±9.5%Aug 17 — IV 108% · EM ±9.0%Aug 18 — IV 135% · EM ±9.7%Aug 19 — IV 43% · EM ±2.5%Aug 20 — IV 151% · EM ±6.3%Aug 24 — IV 53% · EM ±11.1%Aug 25 — IV 52% · EM ±10.6%Aug 26 — IV 54% · EM ±10.7%Aug 27 — IV 58% · EM ±11.4%Aug 28 — IV 55% · EM ±10.5%Aug 31 — IV 45% · EM ±7.9%Sep 01 — IV 62% · EM ±10.8%Sep 02 — IV 52% · EM ±8.6%Sep 03 — IV 62% · EM ±10.0%Sep 04 — IV 68% · EM ±10.6%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in